Did you know that companies like Medimmune and Affymetrix each received SBIR funding during their early stages to help grow their companies and develop compelling new products? There have been exciting new developments with SBIR in the past couple of years that you might not be aware of. Venture-backed small businesses are now eligible to apply and companies can now compete directly for larger Phase II SBIR awards. The National Cancer Institute SBIR & STTR is currently funding 372 projects in the areas of IT, diagnostics, imaging, devices, therapeutics, and tools for basic research? Join us for a chance to hear about the SBIR & STTR funding process and apply for a one-on-one meeting with a representative from the NCI.
The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early stage companies, providing over $115M in fiscal year 2014 to develop next generation technologies. These funding programs help fill the gap in the availability of early stage funding created when investors and strategic partners moved towards clinical-stage investments. SBIR funds serve as a key bridge between initial angel funding and more significant angel capital, venture capital, or strategic partnerships.
Hear from Michael Weingarten, Director for the NCI SBIR Development Center, about the various new NCI SBIR program initiatives and funding opportunities. The presentation will include a discussion of the expanded eligibility for SBIR funding, the new Direct-to-Phase II solicitation, and the NCI SBIR Bridge award which provides an additional $3M in SBIR funding beyond Phase II to match investments by non-federal investors.
Andrew Kurtz, Program Director & Team Leader with the NCI SBIR Development Center, will provide guidance on preparing a competitive application which will include an overview of the elements that NCI looks for when reviewing applications, a discussion on the proper stage of development for each Phase, and answers to FAQs.
Following the presentation and Q&A, don't miss this opportunity to introduce yourself to the NCI SBIR Development Center representatives during the networking lunch. For companies who apply online and are approved, one-on-one meetings with the NCI SBIR program representatives will provide an opportunity to further discuss your company.
Don't miss the opportunity to meet one-on-one with directors from the NCI SBIR Development Center: apply today!
8:30am | Registration and Networking
9:00am | Welcome
9:15am | Presentation and Q&A
11:15am | Networking Lunch
12:00-3:00pm | One-on-one Meetings*
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends April 17. APPLY HERE
National Cancer Institute Participating Representatives:
Michael Weingarten, MS | Director, SBIR Development Center, National Cancer Institute read bio»
Andrew Kurtz, PhD | Program Director & Team Leaders, SBIR Development Center, National Cancer Institute read bio»
Todd Haim, PhD | Program Director, SBIR Development Center, National Cancer Institute read bio»
About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Facts about NCI SBIR/STTR:
• In FY14, the NIH will spend $757M on SBIR/STTR funding, $119M of which will go to NCI
• NCI SBIR & STTR is currently funding 372 projects in the areas of Health IT & Software Tools, Tools for Basic Research, In Vitro Diagnostics, Imaging, Devices for Cancer Therapy, and Therapeutics
• Funding opportunities include the Omnibus Solicitation, Contract Solicitation, Phase IIB Bridge Award, and the IMAT FOA
• There is a new Direct-to-Phase II Pilot Program for SBIR applicants
• Recent NCI SBIR Initiatives include Investor Forums and workshops for portfolio companies
• Awards from the NCI SBIR Development Center are non-dilutive and no repayment is required
• In FY13, SBIR applications from Massachusetts had a 16.8% success rate. The average SBIR success rate for the nation was 15.7%.
• In FY13, STTR applications from Massachusetts had a 25% success rate. The average STTR success rate for the nation was 20.1%.
Presentation & Lunch Only
$25 | General Public
SOLD OUT | General Public Onsite
Includes presentation, Q&A, and lunch. Registration to attend the presentation, Q&A, and lunch will remain open until April 30th.
It is free to apply, but upon acceptance the following fees will apply:
$25 | Accepted Companies
Includes one-on-one meeting only. Companies must have applied for a one-on-one meeting ahead of time. The application period ends on April 17. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Michael Weingarten, MS | Director, SBIR Development Center, National Cancer Institute
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute, one of 27 Institutes of the National Institutes of Health (NIH). In this role, Michael leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of over $115M in grants and contracts annually. Under Michael’s leadership, the NCI SBIR Development Center has launched a range of new programs to facilitate the success of small businesses in the cancer space. One of these new initiatives is a brand new funding program for the NIH known as the SBIR Phase II Bridge Award, which more than triples the amount of funding available to applicants through the NCI SBIR Program. NCI SBIR has also launched an investor forum where potential investors can get a first look at the most promising NCI SBIR companies developing the next generation of cancer therapeutic, diagnostic, or imaging technologies. Prior to joining the NIH, Michael was the manager of partnership development activities for NASA’s Technology Transfer program which included the SBIR program. He played a major role in the creation and design of NASA’s Technology Transfer program – a network of 10 NASA research centers and six regional technology transfer centers. Michael has a bachelor’s degree in political science from Northwestern University and a master’s degree in political science from Columbia University.
Andrew Kurtz, PhD | Program Director, SBIR Development Center, National Cancer Institute
Dr. Kurtz's management portfolio includes both grant and contract awards to support the pre-clinical development of novel oncology therapeutics, including small molecules, biologics, and multifunctional therapeutics based on nanotechnology. From 2005-2007, Dr. Kurtz was a NIH/AAAS Science and Technology Policy Fellow, serving on the management team of The Cancer Genome Atlas Pilot Project and also assisting in the development of several program enhancements to help advance NIH-funded SBIR projects toward commercialization. Prior to coming to NIH, Dr. Kurtz conducted basic research in DNA repair, mutagenesis and carcinogenesis. He held a previous position as Research Associate at Cedra Corporation, a Contract Research Organization that provides GLP bioanalytical services to the pharmaceutical and biotechnology industries. Dr. Kurtz received a B.S. in Chemistry from The University of Texas at Austin, and a Ph.D. in Human Biological Chemistry & Genetics from The University of Texas Medical Branch at Galveston.
Todd Haim, PhD | Program Director, SBIR Development Center, National Cancer Institute
Dr. Todd Haim is a Program Director at the National Cancer Institute’s SBIR Development Center. Dr. Haim manages SBIR & STTR grants and contracts related to cancer therapeutics, prevention, and diagnostics. Additionally, Todd plays a key role in the planning, design, and leadership of several center initiatives, including the Investor Forum, evaluation efforts, targeted solicitations, and outreach activities. Prior to starting in the SBIR Development Center, he was a Research Associate and Christine Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences. Dr. Haim staffed the Committee on Science, Engineering and Public Policy (COSEPUP) and his efforts centered on follow-up activities to the 2005 “Rising Above the Gathering Storm” report related to various innovation initiatives and evaluation programs. Previously, he completed a postdoctoral fellowship at Pfizer in which he actively led Pfizer’s research efforts in a collaboration with Washington University School of Medicine in St. Louis that illustrated a mechanism for altered cardiac contractility due to excess fatty acids. Dr. Haim graduated from Albert Einstein College of Medicine in January 2007 with a PhD in biomedical research. He has received several prestigious awards and honors including the NJ Governor’s Award for Volunteerism in the Field of Health.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, and Thomas McNerney & Partners
When & Where
JLABS @ LabCentral
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas.
JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation, Inc. any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and Johnson & Johnson Innovation JLABS has now two established locations in San Francisco, one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility, and in Boston, through a collaboration with Lab Central. For more information please visit jlabs.jnjinnovation.com.